Wednesday, July 8, 2026

pharma · Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis (PFIC) · MIRM

Mirum Pharmaceuticals International

Mirum Pharmaceuticals International clinical programs — 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US HQ
2018 Founded
436 Employees
Public company Type
MIRM · NYSE Ticker
Company details
Status
Public
HQ
989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404, US
Founded
2018
Employees
436
Programs
25
Drugs
10
Patents
4
Intelligence · Clinical Programs

Mirum Pharmaceuticals International projects

15 ClinicalTrials.gov programs sponsored by Mirum Pharmaceuticals International.

Mirum Pharmaceuticals International has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. LUM001

    Mirum Pharmaceuticals International B.V.

    PBC

    phase 2 small molecule completed

    1 trial
  2. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Biliary Cirrhosis

    phase 2 small molecule terminated

    1 trial
  3. LUM001

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    2 trials
  4. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Sclerosing Cholangitis (PSC)

    phase 2 small molecule completed

    1 trial
  5. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 2 small molecule completed

    1 trial
  6. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    3 trials
  7. Low dose of MRM-3379

    Mirum Pharmaceuticals International B.V.

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial
  8. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Biliary Atresia

    phase 2 small molecule completed

    1 trial
  9. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Cholestatic Liver Disease

    phase 2 small molecule completed

    1 trial
  10. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule active

    1 trial
  11. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis

    phase 2 small molecule completed

    1 trial
  12. SHP626

    Mirum Pharmaceuticals International B.V.

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    3 trials
  13. Volixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule terminated

    1 trial
  14. Volixibat

    Mirum Pharmaceuticals International B.V.

    Primary Biliary Cholangitis

    phase 2 small molecule active

    1 trial
  15. Volixibat

    Mirum Pharmaceuticals International B.V.

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Mirum Pharmaceuticals International have?

15 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.